AzTrials
AzTrials

Inguinal Hernia RepairNCT06389318

Buccal Midazolam Versus Intranasal Dexmedetomidine Plus Oral Chloral Hydrate in Inguinal Hernia Repair

A study testing oral chloral hydrate,intranasal dexmedetomidine and buccal normal saline in people with Inguinal Hernia Repair, run by Benha University at 1 site in Egypt.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Inguinal hernia surgery is one of the most common surgical procedures in early infancy. Preoperative anxiety remains a vexing issue, and it exists in nearly 50% of pediatric patients Read more about this study

Who is it for?
Ages 2 to 7 years
Conditions the study is for
Inguinal Hernia Repair
What is being tested?
oral chloral hydrate,intranasal dexmedetomidine and buccal normal saline
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
80 participants
Where
1 siteEgypt
Study dates
26 Mar 2023to 24 Apr 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 2 to 7 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • aged 2 to 7
  • American Society of Anaesthesiology (ASA) І and П scheduled for inguinal hernia repair

Who cannot join

  • sensitivity to dexmedetomidine or midazolam,
  • infection of the upper respiratory tract,
  • severe liver or kidney disease, organ dysfunction,
  • cardiac arrhythmia or congenital heart disease

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Benha University

    Banhā, 13511

Other trials in Egypt

About this study

Official title: Comparison Between Buccal Midazolam Versus Intranasal Dexmedetomidine Plus Oral Chloral Hydrate in Reducing Parental Separation Anxiety in Children Undergoing Inguinal Hernia Repair: A Randomized Clinical Trial

Inguinal hernia surgery is one of the most common surgical procedures in early infancy. Preoperative anxiety remains a vexing issue, and it exists in nearly 50% of pediatric patients

Read the detailed description

Inguinal hernia surgery is one of the most common surgical procedures in early infancy. Preoperative anxiety remains a vexing issue, and it exists in nearly 50% of pediatric patients.

The administration of sedatives to a child before entering a surgical room is the most common way of reducing the child's distress and allows the child to undergo smooth anesthesia induction.

Chloral hydrate is a widely used sedative for young children undergoing imaging studies, with a high success rate.

Dexmedetomidine is a highly selective alpha-2 agonist for paediatric sedation. It produces sedation like natural non-rapid eye movement sleep and has respiratory-sparing effect.

Being tested
buccal midazolam +oral placebo syrup, oral chloral hydrate,intranasal dexmedetomidine and buccal normal saline
Keywords
Midazolam, Dexmedetomidine, Chloral Hydrate

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • buccal midazolam +oral placebo syrupDrug

    Also called Group A

    Children received oral chloral hydrate (Chloral Hydrate mixture, concentration at 0.5gm/5ml, 250 ml bottle, prepared at abo Elreesh pharmacy, Elmoneerah , Egypt) at 50 mg /kg, intranasal dexmedetomidine at 2 μg/kg and buccal normal saline. Dexmedetomidine used was preservative-free dexmedetomidine (Precedex, 2ml ampoule,100 ug /ml, Hospira, Inc, Rocky Mount, USA) in a concentration of 100 μg/mL. Undiluted drug was withdrawn into a 1 mL tuberculin syringe.

  • oral chloral hydrate,intranasal dexmedetomidine and buccal normal salineDrug

    Also called Group B

    Children received oral chloral hydrate (Chloral Hydrate mixture, concentration at 0.5gm/5ml, 250 ml bottle, prepared at abo Elreesh pharmacy, Elmoneerah , Egypt) at 50 mg /kg, intranasal dexmedetomidine at 2 μg/kg and buccal normal saline. Dexmedetomidine used was preservative-free dexmedetomidine (Precedex, 2ml ampoule,100 ug /ml, Hospira, Inc, Rocky Mount, USA) in a concentration of 100 μg/mL. Undiluted drug was withdrawn into a 1 mL tuberculin syringe.

Study groups in NCT06389318
Study groupRoleWhat they receive
buccal midazolam groupExperimentalChildren received oral placebo syrup, intranasal 0.9 % normal saline at 0.03 ml/kg and buccal midazolam at 0.1 mg/ kg mixed with simple syrup
Receives: Drug: buccal midazolam +oral placebo syrup
oral chloral hydrate and intranasal dexmedetomidine groupExperimentalChildren received oral chloral hydrate (Chloral Hydrate mixture, concentration at 0.5gm/5ml, 250 ml bottle, at 50 mg /kg, intranasal dexmedetomidine at 2 μg/kg and buccal normal saline.
Receives: Drug: oral chloral hydrate,intranasal dexmedetomidine and buccal normal saline

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Ramsay sedation score

    The scoring criteria were as follows: (1) patient shows anxiety and restlessness; (2) patient is cooperative, oriented, and quiet; (3) patient is responsive to instructions; (4) patient shows somnolence and responsive to the tapping of the glabella or to loud auditory stimuli; (5) patient shows somnolence and unresponsive to the tapping of the glabella or to loud auditory stimuli; and (6) patient shows somnolence without any response.

    Measured: RSSs were recorded just immediately before and at 10 minutes , 20 minutes , 30 minutes after dosing

Secondary outcomes (1)
  1. Parental separation anxiety scale

    Parental separation anxiety scale was determined when the child was separated from the parents according to four levels:

    1. easy to separate
    2. sobbing but easy to cease
    3. crying loudly and difficult to stop but without holding the parents and not letting them go
    4. crying loudly and holding the parents and not willing to let them go. PSAS scores of 1 and 2 were considered "successful separation from parents

    Measured: Preoperatively

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Apr 2024
  2. Study start26 Mar 2023
  3. Primary completion26 Mar 2024
  4. Study completion24 Apr 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Model description
Group A (40 patients): Children received oral placebo syrup, Group B (40 patients): Children received oral chloral hydrate (Chloral Hydrate mixture)
Masking
Double blind
Who is masked
Participant, Care provider
Enrolment
80 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06389318
Sponsor's protocol ID
RC 29-11-2023
Status last verified
Apr 2024
First submitted
24 Apr 2024
Last updated
17 May 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: The data will be available upon reasonable request from the principle investigator

Questions about this trial

What is this clinical trial studying?

A study testing oral chloral hydrate,intranasal dexmedetomidine and buccal normal saline in people with Inguinal Hernia Repair, run by Benha University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 17 May 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Ramsay sedation score (time frame: RSSs were recorded just immediately before and at 10 minutes , 20 minutes , 30 minutes after dosing). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 May 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in